First Wave BioPharma, Inc. — Form 10-Q summary
Filing identity: The supplied filing is for First Wave BioPharma, Inc. (Nasdaq: FWBI), not Gridai Technologies Corp. It covers the quarter and six months ended June 30, 2022; the financial statements are unaudited.
Business context and reporting period
The company is a development-stage biotechnology business focused on non-systemic gastrointestinal therapies, including adrulipase for exocrine pancreatic insufficiency and niclosamide for gastrointestinal and inflammatory conditions. It reported no revenue and relies on external financing to fund operations.
Key financial metrics
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Revenue | $0 reported | $0 reported |
| Research and development expense | $2.91 million | $7.88 million |
| General and administrative expense | $2.50 million | $6.90 million |
| Total operating expenses | $5.41 million | $14.79 million |
| Net loss | $5.41 million | $15.03 million |
| Net loss per share, basic and diluted | $0.25 | $0.82 |
| Cash used in operating activities | Not stated for the quarter | $12.50 million |
At June 30, cash and cash equivalents were $1.16 million, total current assets were $1.79 million, and current liabilities were $17.28 million, producing negative working capital of approximately $15.5 million. Total liabilities were $18.12 million, including a $12.0 million current acquisition-related payable and $161,909 of note payable. Stockholders’ deficit was $14.19 million. No meaningful operating margin is available because the company had no reported revenue.
Material changes versus the prior comparable period
- Quarterly operating expenses fell 42% to $5.41 million from $9.28 million; quarterly net loss narrowed 42% to $5.41 million from $9.28 million. Management attributed the R&D decrease mainly to lower clinical-trial costs and the absence of a $1.0 million prior-year license milestone payment.
- Six-month operating expenses declined 15% to $14.79 million from $17.49 million, while net loss narrowed 11% to $15.03 million from $16.96 million. Lower G&A and the absence of prior-year license costs were partly offset by clinical spending and other expenses.
- Six-month operating cash use increased to $12.50 million from $10.70 million. Financing provided $5.44 million, mainly from a March 2022 offering; cash fell by $7.05 million over the six months.
- Cash declined from $8.25 million at December 31, 2021 to $1.16 million at June 30, 2022. Common shares outstanding increased from 14.86 million to 22.70 million over that period.
Outlook, risks, contingencies, and unusual items
- Going concern and funding: Management said June 30 cash plus approximately $4.6 million of net ATM proceeds received through July 14 was expected to fund planned operations only into September 2022. The filing states substantial doubt exists about the company’s ability to continue as a going concern absent additional capital.
- Clinical programs: The Phase 2 RESERVOIR COVID-19 GI trial did not meet its efficacy endpoint, although the drug was reported safe and without serious adverse events. The ulcerative proctitis/proctosigmoiditis trial, concluded in August 2022, also failed to demonstrate efficacy; further study under a different design was under evaluation. The FW-ICI-AC program was on hold for financial reasons. Management expected R&D spending to decline as niclosamide trials neared completion, while adrulipase formulation work continued.
- Acquisition dispute and settlement: The company had suspended payments related to its FWB acquisition, prompting litigation. A July 29, 2022 settlement called for $1.5 million paid on that date, another $1.0 million by September 29, and $2.0 million by the earlier of November 30 or completion of qualifying equity offerings. Payment of the second installment was a condition for dismissal of the action and extinguishment of approximately $12.5 million of fixed obligations. The former owners also retained contingent milestone and asset-sale or licensing participation rights. Failure to meet obligations could lead to further cuts or bankruptcy protection.
- Nasdaq listing: The company was noncompliant with the minimum stockholders’ equity and $1.00 bid-price requirements. Nasdaq granted a continued-listing exception on July 11, subject to conditions including a significant equity financing and stockholder approval of a reverse split; the exception’s final term expired November 22, 2022. Delisting remained a material risk.
- Subsequent financing and dilution: July ATM sales generated approximately $4.8 million gross proceeds, less about $202,000 in costs; the filing also reports approximately $4.6 million net ATM proceeds through July 14. A separate July 15 private placement raised $300,000 gross and included preferred shares convertible into 2.0 million common shares and warrants for 2.0 million shares, plus placement-agent warrants. The filing reports 41,590,308 common shares outstanding as of August 11, versus 22,699,812 at June 30.
- Capital structure: At June 30, 12.49 million warrants and 914,065 options were outstanding, in addition to convertible preferred stock, creating potential dilution. The company also paid approximately $233,000 in Series B waiver fees during the first half.
- Other risks: Management cited clinical and regulatory uncertainty, need for additional capital, COVID-19 effects, geopolitical uncertainty related to the war in Ukraine, and foreign-currency exposure. Disclosure controls were assessed as effective; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether the settlement installments were paid on time and the litigation was dismissed, and what contingent obligations remain.
- Subsequent cash balance, operating cash burn, financing availability, and the timing and terms of any additional capital raises.
- Whether the company satisfied Nasdaq’s financing and reverse-split conditions and regained ongoing listing compliance.
- Updated clinical data and development decisions for adrulipase and niclosamide, including costs and timelines.
- Current fully diluted share count, including July ATM shares, preferred conversions, warrants, and options; reconcile the large increase in reported shares after June 30.